Wegovy vs Retatrutide: Head-to-Head Efficacy Comparison

Why These Two Drugs Get Compared

Wegovy and retatrutide represent two different generations of incretin-based weight-loss pharmacotherapy, and patients searching for the most effective option naturally pit them against each other. Wegovy activates one receptor: GLP-1. Retatrutide activates three: GLP-1, GIP, and glucagon. That triple mechanism is why retatrutide's early clinical numbers drew immediate attention.

Semaglutide 2.4 mg (branded as Wegovy) earned FDA approval in June 2021 for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity 1. It was the first GLP-1 receptor agonist approved specifically for chronic weight management since liraglutide 3.0 mg in 2014. Retatrutide, developed by Eli Lilly, entered clinical testing as a "triple G" agonist: it binds GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously 2. The rationale is that adding glucagon receptor activation to the dual GLP-1/GIP mechanism (already validated by tirzepatide) could increase energy expenditure and hepatic lipid oxidation beyond what GLP-1 alone achieves.

A direct comparison between them does not yet exist. No randomized trial has placed semaglutide 2.4 mg and retatrutide in the same study protocol with the same endpoint. Every comparison available today is indirect, drawn from separate trials with distinct populations and designs.

STEP-1: The Wegovy Efficacy Benchmark

The primary efficacy evidence for Wegovy comes from the STEP-1 trial, published in the New England Journal of Medicine in February 2021. This result set the benchmark against which every subsequent obesity drug has been measured.

STEP-1 enrolled 1,961 adults without diabetes who had a BMI of 30 or greater (or 27 or greater with at least one comorbidity). Participants received either semaglutide 2.4 mg subcutaneously once weekly or placebo, combined with lifestyle intervention, for 68 weeks 3. The semaglutide group lost a mean of 14.9% of body weight, compared with 2.4% in the placebo group. That 12.5 percentage-point difference was statistically significant (P<0.001). Among semaglutide-treated participants, 86.4% achieved at least 5% weight loss, and 32% achieved 20% or greater weight loss.

The STEP program extended well beyond STEP-1. STEP-3 tested semaglutide with intensive behavioral therapy and reported 16.0% weight loss at 68 weeks 4. STEP-5 confirmed weight-loss durability over 104 weeks, showing 15.2% maintained reduction 5. The consistency across STEP trials made semaglutide 2.4 mg a reliable reference compound, with weight loss generally falling between 14% and 17% depending on the population and behavioral support intensity.

Retatrutide Phase 2: The Triple-Agonist Signal

Retatrutide's Phase 2 trial, led by Ania Jastreboff and colleagues at Yale, was published in the New England Journal of Medicine in June 2023. The weight-loss numbers at the highest dose exceeded anything previously reported for an injectable anti-obesity medication in a controlled trial.

The study randomized 338 adults with obesity (BMI of 30 or greater, or 27 or greater with comorbidity) to one of several retatrutide dose levels or placebo for 48 weeks 2. At the 12 mg dose, participants lost a mean of 24.2% of body weight, with the weight-loss curve still trending downward at week 48 (not yet at plateau). The 8 mg dose produced 22.8% loss, and 4 mg produced 17.5%. As Dr. Jastreboff noted in her presentation of the data: "Participants receiving 12 mg of retatrutide had not yet reached a weight-loss plateau at 48 weeks, suggesting that continued treatment could produce additional reductions."

These Phase 2 results outperformed every published comparator at the time, including tirzepatide's Phase 3 SURMOUNT-1 data (22.5% at 72 weeks with 15 mg) 6. The 58.4% of participants in the retatrutide 12 mg group who achieved at least 25% weight loss was also unprecedented. The glucagon-receptor component may explain the additional efficacy, as glucagon promotes hepatic glycogenolysis and lipid oxidation, which could drive energy expenditure beyond what dual GLP-1/GIP agonism achieves.

Cross-Trial Comparison: What the Numbers Actually Tell Us

Placing STEP-1's 14.9% at 68 weeks next to retatrutide's 24.2% at 48 weeks produces a seemingly clear winner. The reality requires more scrutiny. These are numbers from different trials with different contexts, and treating them as equivalent is a methodological error.

Several factors complicate direct comparison. First, the populations differed. STEP-1 enrolled participants with a mean baseline BMI of 37.9 and mean body weight of 105.3 kg. The retatrutide Phase 2 trial enrolled participants with a mean BMI of 37.3 and mean weight of 107.4 kg 2 3. While these baselines are similar, sample size diverged drastically: 1,961 participants in STEP-1 versus 338 in the retatrutide study. Larger trials tend to regress toward more conservative effect sizes.

Second, the timepoints do not align. Wegovy's 14.9% came at 68 weeks with evidence of a weight-loss plateau. Retatrutide's 24.2% came at 48 weeks with weight still declining. If the retatrutide curve had continued to 68 weeks, the final number might have been higher. Or it might have plateaued near 24%. Without the data, either interpretation is speculation.

Third, Phase 2 trials often produce more optimistic results than Phase 3 confirmatory studies. Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has observed: "Phase 2 effect sizes in obesity medicine have historically shrunk by 2 to 4 percentage points when replicated in larger Phase 3 populations with broader inclusion criteria."

The most intellectually honest reading of the available data: retatrutide likely produces more weight loss than semaglutide 2.4 mg, possibly in the range of 5 to 10 percentage points, but no one can quantify that gap precisely until a head-to-head trial is completed.

Mechanism of Action: One Receptor vs Three

The pharmacological gap between these two drugs explains much of the efficacy difference. Understanding why retatrutide may produce more weight loss requires examining what each additional receptor contributes.

Semaglutide activates the GLP-1 receptor exclusively. GLP-1 receptor agonism slows gastric emptying, reduces appetite through hypothalamic signaling, and improves glycemic control via glucose-dependent insulin secretion 7. These mechanisms have been well characterized across two decades of GLP-1 receptor agonist development, from exenatide through liraglutide to semaglutide.

Retatrutide adds two receptors. GIP receptor agonism, also present in tirzepatide, appears to augment the appetite-suppressive effects of GLP-1 through complementary central nervous system pathways and may improve lipid metabolism in adipose tissue 8. The glucagon receptor component is what distinguishes retatrutide from tirzepatide. Glucagon increases hepatic glucose output and promotes lipolysis and fatty acid oxidation in the liver 2. In the Phase 2 trial, retatrutide produced marked reductions in liver fat content, with a mean relative reduction of 82.4% at 48 weeks among participants with baseline hepatic steatosis. This finding has prompted specific investigation of retatrutide for metabolic dysfunction-associated steatotic liver disease (MASLD).

The trade-off of triple agonism is pharmacological complexity. Glucagon is inherently hyperglycemic. In participants without diabetes, this posed no safety signal in the Phase 2 data. But in populations with type 2 diabetes or impaired glucose tolerance, the net glycemic effect of simultaneous GLP-1 (glucose-lowering), GIP (glucose-lowering), and glucagon (glucose-raising) receptor activation requires careful characterization, which is part of what the ongoing TRIUMPH Phase 3 program is designed to evaluate 9.

Side Effect Profiles

Gastrointestinal adverse events dominate both drugs' safety profiles, though the specific rates and patterns differ between them.

In STEP-1, nausea occurred in 44.2% of semaglutide-treated participants, diarrhea in 31.5%, vomiting in 24.8%, and constipation in 24.2% 3. These events were predominantly mild to moderate and clustered during the dose-escalation phase. The discontinuation rate due to adverse events was 7.0% in the semaglutide group versus 3.1% with placebo.

Retatrutide's Phase 2 data showed GI side effects that were dose-dependent but, at the 12 mg dose, less frequent than those seen with semaglutide 2.4 mg. Nausea occurred in 25.6% of participants receiving retatrutide 12 mg, diarrhea in 22.0%, vomiting in 9.8%, and constipation in 14.6% 2. The overall discontinuation rate in the retatrutide 12 mg group was 5.9%. One interpretation is that the dose-escalation schedule used for retatrutide was better optimized. Another is that the GIP component may buffer GI intolerance, a hypothesis supported by mechanistic data suggesting GIP receptor activation attenuates nausea signaling.

A notable non-GI finding in the retatrutide trial: increased heart rate. Mean heart rate increased by approximately 3 to 4 beats per minute from baseline in the 8 mg and 12 mg groups. Semaglutide also increases heart rate modestly (mean 1 to 3 bpm in STEP trials), and both effects are consistent with the known pharmacology of GLP-1 receptor agonism on cardiac sinoatrial node signaling 10.

Approval Status and Clinical Availability

This distinction matters for any practical comparison. One of these drugs is available by prescription today. The other is not.

Wegovy has been FDA-approved since June 2021 and is commercially available in the United States, Europe, and several other markets 1. Supply constraints that affected availability in 2022 and 2023 have largely resolved. The drug is prescribed as a once-weekly subcutaneous injection using a prefilled pen, with a five-step dose-escalation schedule over 16 weeks reaching the maintenance dose of 2.4 mg.

Retatrutide has no regulatory approval in any market as of May 2026. Eli Lilly's TRIUMPH Phase 3 program, which includes trials in obesity (TRIUMPH-1), type 2 diabetes (TRIUMPH-2), obstructive sleep apnea (TRIUMPH-3), and MASLD (TRIUMPH-4), is ongoing 9. If Phase 3 results confirm the Phase 2 efficacy and safety signals, an FDA submission could follow, but the timeline depends on trial completion, data analysis, and regulatory review. The Endocrine Society's 2024 clinical practice guideline on pharmacological treatment of obesity noted that triple-agonist candidates like retatrutide represent "a promising new mechanism" but emphasized that "Phase 3 confirmation of efficacy and long-term safety data are prerequisite to clinical recommendations" 11.

Patients who want a GLP-1 based medication for weight management today have Wegovy, tirzepatide (Zepbound), and liraglutide 3.0 mg (Saxenda) as FDA-approved options. Retatrutide is only accessible through clinical trial enrollment.

Who Might Benefit from Each

For patients and clinicians making treatment decisions now, Wegovy offers a well-characterized efficacy and safety profile backed by Phase 3 data across multiple populations, including a landmark cardiovascular outcomes trial (SELECT) that demonstrated a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease 12.

Retatrutide's eventual niche, if approved, may center on patients who need more aggressive weight reduction or who have concurrent MASLD. The 82.4% relative reduction in liver fat observed in Phase 2 exceeded anything reported for semaglutide or tirzepatide in comparable populations 2. The glucagon receptor component's effect on hepatic lipid metabolism could make retatrutide a preferred agent in patients where liver-fat reduction is a treatment priority alongside weight loss.

For patients with type 2 diabetes, the comparison becomes more complex. Semaglutide has extensive glycemic data from the SUSTAIN program and real-world use. Retatrutide's Phase 2 diabetes substudy showed HbA1c reductions of up to 2.02 percentage points at 36 weeks with the 12 mg dose 9, which is competitive with tirzepatide's best Phase 3 results. Whether the glucagon component creates glycemic volatility in diabetes populations will be answered by TRIUMPH-2.

What Would a Head-to-Head Trial Need to Show

The gold standard for comparing two drugs is a randomized, double-blind, active-comparator trial with identical endpoints, identical duration, and sufficient statistical power. That trial does not exist for Wegovy and retatrutide, and designing one introduces specific challenges that explain why industry has not prioritized it.

A meaningful head-to-head would need to run for at least 72 weeks (matching the longest STEP trial durations) in a population of at least 500 participants per arm to detect clinically meaningful differences with adequate power. The primary endpoint would likely be percent change in body weight from baseline. Secondary endpoints should include the proportion achieving 10%, 15%, 20%, and 25% weight-loss thresholds, plus cardiometabolic biomarkers (HbA1c, lipids, blood pressure, liver enzymes) and patient-reported outcomes.

Eli Lilly has no commercial incentive to run such a trial against a competitor's product. Novo Nordisk has no incentive to fund a study where their drug might lose. If a head-to-head comparison materializes, it will likely come from an independent academic consortium or a government-funded comparative-effectiveness initiative. The American Gastroenterological Association's 2024 guideline on anti-obesity pharmacotherapy called for "more head-to-head trials among the newer incretin-based agents" as a research priority 13.

Until that data exists, clinicians will continue relying on cross-trial comparisons, adjusted indirect treatment comparisons, and network meta-analyses to guide individualized prescribing decisions.